Skip to main content
SpringerLink
Log in

Acute mucocutaneous toxicity following high-dose hydroxyurea

  • Short Communication
  • High-Dose Hydroxyurea, Mucocutaneous Toxicity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Three patients with advanced acute myeloid leukemia were treated with oral high-dose hydroxyurea at a dose of 10 g daily for 8–10 days. Severe acute stomatitis developed in all three patients. In addition, two of the patients developed a peculiar acute cutaneous type of toxicity associated with soreness, violet erythema, and edema of the palms and foot soles followed by intense universal hyperpigmentation of the skin. Apparently, the pronounced acute mucocutaneous toxicity was caused by the sustained high daily dose of hydroxyurea, indicating that myelosuppression may not be the dose-limiting toxicity of this drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Donehower RC (1992) An overview of the clinical experience with hydroxyurea. Semin Oncol 19 [Suppl 8]: 11

    Google Scholar 

  2. Grund FM, Armitage JO, Burns CP (1977) Hydroxyurea in the prevention of the effects of leucostasis on acute leukemia. Arch Intern Med 137: 1246

    Google Scholar 

  3. Kennedy BJ (1992) The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin Oncol 19 [Suppl 8]: 21

    Google Scholar 

  4. Kennedy BJ, Smith LR, Goltz RW (1975) Skin changes secondary to hydroxyurea. Arch Dermatol 111: 183

    Google Scholar 

  5. Kolitz JE, Kempin SJ, Schluger A, Wong GY, Berman E, Jhanwar S, Arlin ZA, Gee T, Clarkson BD (1992) A phase II pilot trial of high-dose hydroxyurea in chronic myciogenous leukemia. Semin Oncol 19 [Suppl 8]: 27

    Google Scholar 

  6. Landgren RC, Hussey DH, Barkley HT, Samucls ML (1974) Splitcourse irradiation compared to split-course irradiation plus hydroxryurea in operable bronchogenic carcinoma. Cancer 34: 1598

    Google Scholar 

  7. Lokich JJ, Moore C (1984) Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101: 798

    Google Scholar 

  8. Vaughan WP, Bierman PJ, Reed EC, Glenn LD, Kessinger A, Armitage JO (1992) High dose hydroxyurea in autologous bone marrow transplantation: a promising “new” agent. Semin Oncol 19 [Suppl 8]: 110

    Google Scholar 

  9. Veale D, Cantwell BMJ, Kerr N, Upfold A, Harris AL (1988) Phase I study of high-dose hydroxyurea in lung cancer. Cancer Chemother Pharmacol 21: 53

    Google Scholar 

  10. Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19 [Suppl 8]: 1

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Odense University Hospital, DK-5000, Odense C, Denmark

    Hans Brincker & Bjarne Egelund Christensen

Authors
  1. Hans Brincker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bjarne Egelund Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brincker, H., Christensen, B.E. Acute mucocutaneous toxicity following high-dose hydroxyurea. Cancer Chemother. Pharmacol. 32, 496–497 (1993). https://doi.org/10.1007/BF00685897

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685897

Keywords

Search

Navigation